Asclepias currasavica- A multicentric, randomized, double-blind homoeopathic pathogenetic trial

Objective: To elicit the pathogenetic response of the drug Asclepias currasavica in homoeopathic potencies on healthy human beings. Methodology: Drug Asclepias currasavica was proved by the Central Council for Research in Homoeopathy through randomized, double-blind, placebo-controlled method. The study was conducted at four centers. The drug was proved in two potencies (6C and 30C) on 67 apparently healthy volunteers who were selected after conducting pre-trial medical examination by the medical specialists and routine laboratory investigations. In the first phase volunteers were given 56 doses (04 doses per day for 14 days) of placebo. In the next two phases 56 doses (04 doses per day for 14 days) of each potency or placebo were consumed. The symptoms generated during the trial period were noted by the volunteers and elaborated by the Proving Masters. The data obtained from all the four centers was compiled at proving-cum-data processing cell at CCRH headquarters after de- coding. Observations: Out of the 44 provers who were on actual drug trial, 21 manifested symptoms. Drug was able to produce symptoms in both the potencies more or less related to every part of the body. Conclusion: The pathogenetic responses elicited during the proving trial expands the scope of use of the drug Asclepias currasavica and will benefit the research scholars and clinicians. These symptoms will carry more value when verified clinically.